Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flomoxef. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 4/20 | 0.58 |
| ▸ | PGR | P06401 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.57 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.57 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.51 |
| ▸ | APEX1 | P27695 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxalactam SCHEMBL22205083 | 0.85 | NR1I2 (0.52) | NR1I2PGRMAPTPPARGSLC22A6 | |
| Moxalactam SCHEMBL6521966 | 0.84 | NR1I2 (0.64) | NR1I2PGRMAPTPPARGSLC22A6 | |
| SCHEMBL11463469 | 0.81 | NR1I2 (0.86) | NR1I2PGRMAPTPPARGSLC22A6 | |
| SCHEMBL11463468 | 0.81 | NR1I2 (0.86) | NR1I2PGRMAPTPPARGSLC22A6 | |
| Hydrochloric Acid SCHEMBL11481370 | 0.81 | NR1I2 (0.85) | NR1I2PGRMAPTPPARGSLC22A6 | |
| Hydrochloric Acid SCHEMBL11481373 | 0.81 | NR1I2 (0.85) | NR1I2PGRMAPTPPARGSLC22A6 | |
| Moxalactam SCHEMBL28086495 | 0.80 | NR1I2 (0.69) | NR1I2PGRMAPTPPARGSLC22A6 | |
| Cefotiam SCHEMBL3867507 | 0.78 | TDP1 (0.75) | NR1I2PGRMAPTPPARGSLC22A6 | |
| Flomoxef SCHEMBL14423926 | 0.78 | PTGS1 (0.57) | TDP1HSD17B10PTGS1 | |
| Flomoxef SCHEMBL49438 | 0.78 | PTGS1 (0.57) | TDP1HSD17B10PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131665-B2 | Processes for producing diazabicyclooctane compounds | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-11-20 | — | — | US | disclosed |
| US-20160272641-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272641-A1 | CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVE AND PRODUCTION PROCESS THEREOF | DDT, CYP51A1, ODC1 | NR1I2 3784/4885PGR 4083/4885MAPT 2689/4885 |
| US-10131665-B2 | Processes for producing diazabicyclooctane compounds | DDT, ODC1, CYP51A1 | NR1I2 4663/4885PGR 3719/4885MAPT 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.